Skip to content

THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY)

THe effect of canagliflozin on active GLP-1 levels and betatrophin in patients with type 2 diabetes (CANARIA-STUDY) - THe effect of canagliflozin on active GLP-1 levels and betatrophin (CANARIA STUDY)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016539
Enrollment
40
Registered
2015-02-15
Start date
2015-02-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

3 days canagliflozin (100 mg 1x before breakfast) treatment with diet treatment Thereafter addition of teneligliptin (20 mg 1x before breakfast) for 3 days 3 days diet treatment Thereafter addition

Sponsors

Dokkyo Medical University Koshigaya Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) patients (male or femal) aged 20 or over at enrollment 2) patients diagnosed as type 2 diabetes (based on criteria in Japan Diabetes Society 2010) 3)patients with diet and exercise therapy for diabetes during 12 weeks or over before enrollment (if patients have severe diabetic complication, diet therapy alone is applicable) 4)patients in whom type and dose of all anti-diabetic drugs was not changed during 4 weeks before starting study 5)patients who did not receive DPP4 inhibitors, GLP-1 receptor agonist, SGLT2 inhibitors during 1 month before starting study 6) patients with HbA1c more than or equal to 6.5% at enrollment 7)Patients who are hospitalized for glycemic control for type 2 diabetes 8)patients giving consent in writing for participation for this study

Exclusion criteria

Exclusion criteria: 1)Patients with type 1 diabetes, pancreatic diabetes or secondary diabetes (Cushing syndrome, acromegaly etc.) diabetic coma or diabetic pre-coma, or type 1 diabetes 2)Patients who are not candidated for canagliflozin or teneligliptin treatment 3)Patients under insulin treatment 4)Heavy alcohol consumer (more than or equal to 60 g/day of pure alcohol ) 5)Patients under pregnancy, possible pregnancy, or lactation 6)Patients with severe renal dysfunction (Cr >2.4 mg/dL or Ccr <30 mL/min) 7)Furthermore, patients judged as inadequacy for participation in this study by medical doctor

Design outcomes

Primary

MeasureTime frame
Fasting plasma glucose, glucose after meal test, active plasma GLP-1 level, active serum betatrophin level

Secondary

MeasureTime frame
Plasma GIP level

Countries

Japan

Contacts

Public ContactKohzo Takebayashi

Dokkyo Medical University Koshigaya Hospital Internal Medicine (Diabetes, Endocrinology, Hematology)

takebaya@dokkyomed.ac.jp048-965-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026